Ask about this productRelated genes to: GZMA antibody
- Gene:
- GZMA NIH gene
- Name:
- granzyme A
- Previous symbol:
- HFSP, CTLA3
- Synonyms:
- -
- Chromosome:
- 5q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1988-05-31
- Date modifiied:
- 2016-10-05
Related products to: GZMA antibody
Related articles to: GZMA antibody
- Neurodegenerative diseases are increasingly recognized as disorders shaped not only by intrinsic neuronal vulnerability, but also by chronic neuroinflammation mediated by maladaptive neuroimmune signaling. Granzymes, a family of serine proteases classically studied for their cytotoxic roles in anti-viral and anti-tumor immunity, are emerging as important mediators of central nervous system (CNS) pathology. In addition to their canonical intracellular functions, granzymes can act extracellularly to cleave the extracellular matrix (ECM), activate cell-surface receptors, disrupt epithelial barrier function, amplify inflammatory cascades, and alter glial and neuronal responses to injury. In this review, we synthesize current knowledge on the roles of Granzyme A (GzmA), Granzyme B (GzmB), Granzyme H (GzmH), and Granzyme K (GzmK) in neurodegeneration and neuroinflammation across diverse CNS disease and injury contexts, such as Alzheimer's disease (AD), multiple sclerosis (MS), stroke, spinal cord injury (SCI), and age-related macular degeneration (AMD). GzmB is the most extensively characterized, with evidence supporting both intracellular neurotoxicity and extracellular pathogenic functions mediated through protease-activated receptor signaling, ECM cleavage, outer blood-retina barrier disruption, angiogenesis, fibrosis, and chronic inflammation. GzmA is implicated in tau proteolysis and structural destabilization of neurons and astrocytes, while GzmK has emerged as a context-dependent regulator of neuroinflammation through PAR-1 activation, microglial modulation, and complement cascade activation. GzmH remains the least understood but may contribute to nerve injury through mechanisms that are only beginning to be defined. We also discuss endogenous and pharmacological granzyme inhibition, highlighting the therapeutic promise of selective extracellular granzyme targeting, particularly for GzmB, while emphasizing the current lack of selective inhibitors for GzmA, GzmK, and GzmH. Collectively, these findings position granzymes as underappreciated neuroimmune effectors and potential therapeutic targets in neurodegenerative diseases and CNS injury. - Source: PubMed
Publication date: 2026/08/18
Yoo Hyung-SukYu PhilipZhou CeresHosseini AmirGranville David JMatsubara Joanne A - Allergic rhinitis (AR) is a prevalent condition characterized by an immunoglobulin E (IgE)-mediated immune response. T follicular helper (TFH) cells regulate B-cell differentiation and antibody production, and circulating TFH2 cells are closely associated with type 2 humoral immunity and IgE-related responses in AR. However, whether AR is marked by isolated TFH2 expansion or broader remodeling of circulating TFH (cTFH) subsets, including TFH1-related heterogeneity, remains unclear. - Source: PubMed
Publication date: 2026/07/30
He JiejunSun YueqiChen YangLai YinyanLei HanShi JianboGao Wenxiang - Colorectal cancer (CRC) exhibits a highly heterogeneous tumor immune microenvironment (TME), ranging from "immune-inflamed" to "immune-desert" or "immune-excluded" phenotypes. Understanding how immune cell composition, cytolytic activity (CYT) and genomic alternations shape tumor-immune interactions is critical for improving immunotherapy outcomes. We analyzed TCGA-COAD and TCGA-READ datasets to evaluate immune competency, CYT, immune subtypes, microsatellite instability (MSI), and genomic instability, including somatic mutations, copy number aberrations (CNAs), and chromothriptic events. Immune cell infiltration was correlated with CYT levels, immune checkpoint expression, and immune-related gene signatures. Immune-competent (IC) tumors were predominantly CYT-high, enriched in stromal and immune scores, and exhibited distinct TME characteristics compared with immune-deficient (ID) tumors. IC/CYT-high tumors expressed higher levels of immune checkpoints (PD-1, PD-L1, CTLA-4, IDO1/2, LAG-3) and cytokines/chemokines (C1QA/B/C, CXCL9/10/11, CXCL13). Differences in immune infiltration were observed across tumors with significant mutations and copy number alterations. No prognostic difference was observed between CYT-high and CYT-low patients, indicating that CYT reflects immune activation rather than clinical outcome. Functionally, stimulated CD8 T cells exhibited cytotoxicity activity against MSI-high (HCT-116) and microsatellite-stable (HT-29) CRC cells, with MSI-H cells showing higher sensitivity. Dynamic 3D co-culture demonstrated tumor-guided T cell infiltration and retention of CD8 expression, and co-culture was associated with moderate upregulation of cytotoxicity-related genes GZMA and PRF1 within the system. Cytotoxic activity decreased at lower effector-to-target ratios, highlighting the importance of effector dose. Overall, these findings link CYT, immune competency, MSI status, and genomic instability to T cell cytotoxic responses, providing insights into tumor-immune interactions, and suggest potential associations relevant for immunotherapy research in CRC. - Source: PubMed
Publication date: 2026/07/10
Agioti StephanieGeorgoulias GeorgeGeorgakopoulos-Soares IliasChristodoulou Maria-IoannaZaravinos Apostolos - Endometrial injury-related disorders, including intrauterine adhesions, thin endometrium, and chronic endometritis, are a major cause of female infertility. Conventional therapeutic approaches, primarily hormone therapy and surgical interventions, show limited effectiveness in patients with moderate to severe endometrial damage. In this context, regenerative medicine has emerged as a promising direction to overcome current therapeutic limitations and promote functional reconstruction of the endometrium. A comprehensive literature search was conducted across PubMed, Web of Science, Embase, and Scopus to identify relevant studies on endometrial repair and regenerative medicine. The search covered publications from January 2000 to August 2025. The following keyword combinations and MeSH terms were used: ("endometrial repair" OR "endometrial regeneration" OR "intrauterine adhesion" OR "Asherman syndrome" OR "thin endometrium" OR "chronic endometritis") AND ("mesenchymal stem cells" OR "platelet-rich plasma" OR "exosomes" OR "extracellular vesicles" OR "biomaterials" OR "hydrogel" OR "scaffold" OR "regenerative medicine"). Both basic science investigations and clinical studies were included to provide a comprehensive overview of current developments in the field. To minimize the risk of omission, the reference lists of included articles and relevant reviews were manually screened, and potentially pertinent studies were further evaluated. Inclusion criteria: (1) Original research articles or meta-analyses; (2) Focus on therapeutic interventions for endometrial regeneration; (3) Human clinical studies or mammalian animal models. Exclusion criteria: (1) Non-English articles, letters, conference proceedings, etc.; (2) Purely descriptive studies of endometrial physiology without therapeutic intervention, articles lacking quantitative data or sufficient methodological details. The screening process followed the PRISMA 2020 guidelines (Fig. 1). After removing duplicates, 1936 records were screened by title and abstract, and 605 full-text articles were assessed for eligibility. Finally, 102 studies were included in this qualitative synthesis. This review provides a systematic synthesis of recent advances in cell-based therapies, cell-free approaches, and bioengineering strategies for endometrial repair. Evidence derived from different sources of mesenchymal stem cells, including bone marrow, umbilical cord, and endometrium, is comparatively evaluated alongside platelet-rich plasma and extracellular vesicles, with an emphasis on hierarchical assessment of evidence levels. Several critical issues are further examined. Current stem cell-based interventions are largely characterized by a broad reparative profile, yet precise targeting of key molecular mechanisms remains insufficient. To date, no studies have demonstrated the capacity to directly reverse suppression of signaling pathways such as the GZMA-PARD3 axis or to restore depleted regenerative stromal subpopulations, including IGFBP3⁺ cells. Clinical investigations of platelet-rich plasma exhibit substantial heterogeneity, which appears to stem mainly from the absence of standardized preparation protocols and the frequent reliance on surrogate endpoints, particularly endometrial thickness. However, the predictive value of endometrial thickness for live birth is limited, and its use as a primary endpoint may overestimate clinical benefit. Therefore, emphasis should shift toward patient-centered outcomes such as live birth rate. Concerns also arise regarding the degradation kinetics of biomaterials, as mismatches between material resorption and the cyclical regenerative dynamics of the endometrium may increase the risk of secondary adhesions. In addition, the actual delivery efficiency of microneedle-based systems within the enclosed and humid uterine environment has not yet been fully clarified. Based on this critical appraisal, we propose a translational framework that links mechanistic discovery with precision intervention. The importance of long-term follow-up is emphasized, with live birth rate regarded as a more clinically meaningful primary endpoint for evaluating therapeutic efficacy in endometrial regenerative medicine. Endometrial regenerative medicine is transitioning from empirical repair toward mechanism-informed reconstruction. Current evidence is dominated by short-term (< 12 months), small-sample (n < 50) exploratory studies with high interventional heterogeneity. Clinical translation will require unified preparation standards, individualized treatment strategies, and well-designed multicenter randomized controlled trials with live birth rate as the primary endpoint and minimum 2-year follow-up. - Source: PubMed
Publication date: 2026/07/27
Xie MengqiCao YunguiTang JiangpingLi FangDeng Juan - To systematically evaluate the impact of androgen deprivation therapy (ADT) on the immune microenvironment of prostate cancer at the levels of systemic immunity, animal model transcriptomics, and single-cell omics, and to elucidate the characteristics of ADT-mediated tumor immune remodeling. - Source: PubMed
Tan ZhongyuDU YiqingQin CaipengXu Tao